GlassScriptPhysician profile
Lawrence K Weiner
NPI 1508816901
$5,420.66
in general payments reported to CMS, 2019-2025
35 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $771 · 2021: $1,002 · 2022: $872 · 2023: $753 · 2024: $611 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.61 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,217.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $739.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $503.55 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Amarin Pharma, INC. | $292.77 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.34 | 2019-2024 | Ofev |
| Amgen INC. | $252.53 | 2021-2025 | Krystexxa, Repatha, Repatha |
| Mylan Specialty L.P. | $238.07 | 2019-2023 | Yupelri |
| Lilly USA, LLC | $228.53 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $197.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $189.20 | 2019-2025 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $175.40 | 2019-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $165.89 | 2019-2024 | |
| Pfizer INC. | $133.82 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $116.76 | 2019-2025 | Capvaxive, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $91.78 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $85.08 | 2019-2025 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $72.79 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.86 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $34.96 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $32.94 | 2020 | |
| Exact Sciences Corporation | $24.60 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $23.61 | 2019 | |
| Nestle Healthcare Nutrition INC. | $22.84 | 2023 | |
| Allergan, INC. | $22.05 | 2020 | |
| Sanofi Pasteur INC. | $21.30 | 2020 | |
| Esperion Therapeutics, INC. | $21.05 | 2021 | |
| Dexcom, INC. | $19.31 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $19.01 | 2021 | |
| Sumitomo Pharma America, INC. | $15.29 | 2024 | Gemtesa |
| Amag Pharmaceuticals, INC. | $15.07 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
| Abbott Laboratories | $13.30 | 2023 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $13.03 | 2021 | |
| Astellas Pharma US INC | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.